VIATRIS INC
Fiscal years labelled by the calendar year in which they end. Bars in $ billions; per-share figures as reported.
CAPITALIZATION 12/31/25
| ($ millions) | Amount | % |
|---|---|---|
| Total debt | 14,414 | 49.5 |
| Stockholders' equity | 14,711 | 50.5 |
| Total capitalization | 29,125 | 100.0 |
1,148,590,864 shares outstanding at 3 August 2026 (cover page of the 10-Q filed 6 August 2026).
LONG-TERM DEBT 12/31/25
| ($ millions) | Amount |
|---|---|
| Long-term debt, noncurrent | 12,481 |
| Current maturities | 1,933 |
CAPITAL STOCK 12/31/25
| Common shares authorized | 3,000,000,000 |
| Par or stated value per share ($) | 0.01 |
| Outstanding at 8/3/26 | 1,148,590,864 |
DIVIDENDS DECLARED/PAID
| Fiscal year | Per share $ | Payout % |
|---|---|---|
| 2025 | 0.48 | – |
| 2024 | 0.48 | – |
| 2023 | 0.48 | 960.0 |
| 2022 | 0.48 | 28.1 |
| 2021 | 0.33 | – |
HISTORY AND BUSINESS
HISTORY: Incorporated in Delaware. Formerly known as Upjohn Inc (to 10 November 2020).
BUSINESS: Classified by the SEC under Standard Industrial Classification 2834, Pharmaceutical Preparations. Large accelerated filer. Principal executive office: 1000 Mylan Boulevard, Canonsburg, PA 15317. Fiscal year ends December 31. For a description of the business, see Item 1 of the latest 10-K.
CONSOLIDATED INCOME ACCOUNT, YEARS ENDED
| ($ millions) | 12/31/25 | 12/31/24 | 12/31/23 |
|---|---|---|---|
| Revenues | 14,250 | 14,693 | 15,388 |
| Cost of revenues | 9,286 | 9,116 | 8,988 |
| Gross profit | 5,014 | 5,624 | 6,439 |
| Research and development | 966 | 809 | 805 |
| Selling, general and administrative | 3,794 | 4,105 | 4,070 |
| Depreciation and amortization | 2,798 | 2,893 | 2,740 |
| Operating income | (2,663) | 10 | 766 |
| Interest expense | 471 | 550 | 573 |
| Income before income taxes | (3,665) | (623) | 203 |
| Income taxes | (150) | 11 | 148 |
| Net income | (3,515) | (634) | 55 |
| Earned per share, diluted ($) | (3.00) | (0.53) | 0.05 |
| Dividends per share ($) | 0.48 | 0.48 | 0.48 |
CONSOLIDATED BALANCE SHEET
| ($ millions) | 12/31/25 | 12/31/24 |
|---|---|---|
| Cash and equivalents | 1,322 | 735 |
| Receivables, net | 3,031 | 3,221 |
| Inventories | 3,999 | 3,854 |
| Total current assets | 9,789 | 9,521 |
| Property, plant and equipment, net | 2,614 | 2,666 |
| Goodwill | 6,755 | 9,133 |
| Total assets | 37,193 | 41,501 |
| Total current liabilities | 7,094 | 5,779 |
| Long-term debt | 12,481 | 14,039 |
| Total liabilities | 22,482 | 22,865 |
| Total liabilities and equity | 37,193 | 41,501 |
TEN-YEAR STATISTICS: FISCAL YEARS ($ millions except per share)
| Fiscal year ended | Revenues | Oper. income | Net income | Net margin % | EPS diluted $ | Div. per share $ | Oper. cash flow | Capital expend. | Free cash flow | Total assets | Total liabilities | Total debt | Stockholders' equity | ROE % | Debt / equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12/31/25 | 14,300 | (2,663) | (3,515) | -24.6 | (3.00) | 0.48 | 2,316 | 379 | 1,937 | 37,193 | 22,482 | 14,414 | 14,711 | -23.9 | 0.98 |
| 12/31/24 | 14,739 | 10 | (634) | -4.3 | (0.53) | 0.48 | 2,303 | 326 | 1,977 | 41,501 | 22,865 | 14,047 | 18,636 | -3.4 | 0.75 |
| 12/31/23 | 15,427 | 766 | 55 | 0.4 | 0.05 | 0.48 | 2,900 | 377 | 2,523 | 47,686 | 27,218 | 18,132 | 20,467 | 0.3 | 0.89 |
| 12/31/22 | 16,263 | 1,615 | 2,079 | 12.8 | 1.71 | 0.48 | 2,999 | 406 | 2,593 | 50,022 | 28,950 | 19,274 | 21,072 | 9.9 | 0.91 |
| 12/31/21 | 17,886 | (34) | (1,269) | -7.1 | (1.05) | 0.33 | 3,017 | 457 | 2,560 | 54,843 | 34,350 | 23,088 | 20,493 | -6.2 | 1.13 |
| 12/31/20 | 11,946 | (211) | (670) | -5.6 | (1.11) | – | 1,232 | 243 | 989 | 61,553 | 38,599 | 25,839 | 22,954 | -2.9 | 1.13 |
| 12/31/19 | 11,500 | 716 | 17 | 0.1 | 0.03 | – | 1,804 | 213 | 1,590 | 31,256 | 19,372 | 12,722 | 0 | – | – |
| 12/31/18 | 11,434 | 906 | 352 | 3.1 | 0.68 | – | 2,342 | 252 | 2,090 | – | – | – | 12,167 | 2.9 | – |
Net margin = net income ÷ revenues; ROE = net income ÷ year-end stockholders’ equity; total debt = long-term debt including current maturities plus short-term borrowings/commercial paper, as tagged in XBRL; free cash flow = operating cash flow − purchases of property, plant and equipment; d = derived as total assets − total equity where the filing does not tag total liabilities; – = not reported in XBRL for that year.
REGISTRANT:
Viatris Inc
CIK 1792044 · EIN 83-4364296
PRINCIPAL OFFICE:
1000 Mylan Boulevard, Canonsburg, PA 15317
Tel.: (724) 514-1465
INCORPORATED:
Delaware
INDUSTRY (SEC SIC CODE):
2834 · Pharmaceutical Preparations
FILER STATUS:
Large accelerated filer
LATEST ANNUAL REPORT:
10-K for period ended 12/31/25, filed 26 February 2026
FORMER NAMES:
Upjohn Inc
Sources: SEC XBRL company facts (all financial figures) · SEC submissions (registrant, address, SIC, filings) · annual reports: 10-K FY2025 (filed 2/26/26) · 10-K FY2024 (filed 2/27/25) · 10-K FY2023 (filed 2/28/24) · 10-K FY2022 (filed 2/27/23) · 10-K FY2021 (filed 2/28/22) · 10-K FY2020 (filed 3/1/21). Values are the latest figures filed for each fiscal year (restated where a later 10-K restated them). Ratios and free cash flow are Pathos calculations from those figures. Retrieved 31 October 2026.
Data from SEC filings. © 2026 Pathos Investments · pathosinvestments.com · For educational purposes only. Not investment advice.